HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Multiple myeloma is a type of cancer that originates in plasma cells, a type of white blood cell. These cells are crucial for the immune system as they produce antibodies to help fight infections. In multiple myeloma, abnormal plasma cells accumulate in the bone marrow, leading to the production of excess proteins and interference with normal blood cell production. Common symptoms of multiple myeloma include bone pain, fatigue, weakness, frequent infections, and unexplained weight loss. As the disease progresses, it can result in bone damage, kidney problems, and impaired immune function. The exact cause of multiple myeloma is unclear, but certain risk factors such as age, family history, and certain genetic abnormalities may contribute to its development. Diagnosis often involves blood tests, bone marrow biopsy, and imaging studies. Treatment options for multiple myeloma aim to manage symptoms, slow disease progression, and improve quality of life. Therapies may include chemotherapy, immunomodulatory drugs, targeted therapies, stem cell transplant, and supportive care measures. While there is currently no cure for multiple myeloma, advancements in research and treatment have improved outcomes for many patients. The prognosis varies based on factors such as the stage at diagnosis, overall health, and response to treatment. Regular medical monitoring, adherence to treatment plans, and lifestyle adjustments are essential components of managing multiple myeloma. Patients are encouraged to work closely with their healthcare team to tailor a comprehensive care approach suited to their individual needs and circumstances.
